Related Experiment Videos
[Intratympanic gentamicin in Menière's disease]
Weining Huang1, Huijie Xu, Bo Gao
1Department of Otorhinolaryngology, Beijing Hospital, Ministry of Health, Beijing, 100730, China.
Lin Chuang Er Bi Yan Hou Ke Za Zhi = Journal of Clinical Otorhinolaryngology
|April 20, 2004
Summary
Intratympanic gentamicin injections effectively controlled Meniere's disease vertigo in 92.3% of patients. However, this treatment carries a risk of hearing toxicity, particularly at higher frequencies.
Area of Science:
- Otolaryngology
- Nephrology
- Pharmacology
Context:
- Meniere's disease is a chronic inner ear disorder characterized by vertigo, tinnitus, and hearing loss.
- Intractable vertigo in Meniere's disease often requires aggressive treatment options.
- Intratympanic gentamicin injection is a minimally invasive therapeutic approach.
Purpose:
- To evaluate the efficacy and ototoxicity of intratympanic gentamicin injections for managing Meniere's disease.
- To assess the long-term effects of the treatment on vertigo control and hearing thresholds.
Summary:
- Thirteen patients with unilateral Meniere's disease received weekly intratympanic gentamicin injections for two weeks.
- Vertigo was controlled in 12 patients (92.3%) over a two-year follow-up period.
- Significant hearing threshold increases were observed in 23.1% of patients at 8.0 kHz post-treatment and in 69.2% by 18-24 months.
Impact:
- Intratympanic gentamicin offers a simple, cost-effective solution for intractable Meniere's disease vertigo.
- The treatment demonstrates a significant risk of hearing impairment, necessitating careful patient selection and monitoring.
- Further research is needed to optimize gentamicin dosage and administration to minimize ototoxicity while maximizing therapeutic benefits.